Isofol Medical AB (ISOFOL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Isofol Medical AB (ISOFOL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014069
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company developing folate-based therapies for the treatment of cancer patients. The company’s clinical lead candidate Modufolin, a metabolite is under clinical phase I/II development being evaluated for the treatment of colorectal cancer and osteosarcoma. Isofol’s product helps in improving efficacy and reducing side effects of antimetabolites in cancer treatments. Isofol’s focuses to improve the outlook of cancer patients undergoing chemotherapy treatments It also offers research and development services. The company works in collaboration with Merck & Cie , Recipharm AB. Isofol is headquartered in Gothenburg, Sweden.

Isofol Medical AB (ISOFOL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Isofol Medical AB, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Isofol Medical Raises USD1.2 Million in Venture Financing 10
Licensing Agreements 11
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 11
Equity Offering 12
Isofol Medical Raises USD48.6 Million in IPO 12
Isofol Medical Raises USD4.7 Million in Public Offering of Shares 13
Isofol Medical AB – Key Competitors 14
Isofol Medical AB – Key Employees 15
Isofol Medical AB – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Isofol Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Isofol Medical AB, Deals By Therapy Area, 2011 to YTD 2017 8
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Isofol Medical Raises USD1.2 Million in Venture Financing 10
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 11
Isofol Medical Raises USD48.6 Million in IPO 12
Isofol Medical Raises USD4.7 Million in Public Offering of Shares 13
Isofol Medical AB, Key Competitors 14
Isofol Medical AB, Key Employees 15

★海外企業調査レポート[Isofol Medical AB (ISOFOL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Koninklijke Ahold Delhaize NV (AD):企業の財務・戦略的SWOT分析
    Koninklijke Ahold Delhaize NV (AD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Premier Farnell Ltd:企業の戦略的SWOT分析
    Premier Farnell Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Burns & McDonnell:企業の戦略・SWOT・財務情報
    Burns & McDonnell - Strategy, SWOT and Corporate Finance Report Summary Burns & McDonnell - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Biocare Medical LLC-医療機器分野:企業M&A・提携分析
    Summary Biocare Medical LLC (Biocare) develops and supplies automated immunohistochemistry instrumentation and reagents. The company offers androgen receptor, amyloid A, estrogen receptor, ERG, factor xlla and folate receptor alpha IHC assay kit, among others. It offers on-site training, technical s …
  • AFFiRiS AG-製薬・医療分野:企業M&A・提携分析
    Summary Affiris AG (AFFiRiS) is a drug development company that develops and manufactures novel synthetic vaccines against chronic diseases. The company develops customized peptide vaccines based on its proprietary affitome technology for the prevention of Alzheimer's disease, Parkinson's disease, a …
  • Dakota Valley Electric Cooperative:企業の戦略的SWOT分析
    Dakota Valley Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Yomeishu Seizo Co Ltd (2540):企業の財務・戦略的SWOT分析
    Yomeishu Seizo Co Ltd (2540) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • JRI Orthopaedics Ltd:企業の製品パイプライン分析2018
    Summary JRI Orthopaedics Ltd (JRI) a subsidiary of Orthopaedic Research UK (ORUK), is a manufacturer of orthopaedic implants and surgical instruments. The company develops products for joint replacement, repair and reconstruction. It offers products for shoulder and knee arthoplasty, besides customi …
  • Arriva plc:企業の戦略・SWOT・財務情報
    Arriva plc - Strategy, SWOT and Corporate Finance Report Summary Arriva plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ADMA Biologics Inc (ADMA):企業の財務・戦略的SWOT分析
    ADMA Biologics Inc (ADMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Briggs & Stratton Corp (BGG):企業の財務・戦略的SWOT分析
    Briggs & Stratton Corp (BGG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Titan Cement Company Sa
    Titan Cement Company Sa - Strategy, SWOT and Corporate Finance Report Summary Titan Cement Company Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Achaogen Inc (AKAO)-製薬・医療分野:企業M&A・提携分析
    Summary Achaogen Inc (Achaogen) is a biopharmaceutical company that discovers, develops and commercializes novel anti bacterials for the treatment of multi-drug resistant and gram-negative infections. The company is developing plazomicin for the treatment of serious bacterial infections due to MDR E …
  • Exact Sciences Corp (EXAS)-製薬・医療分野:企業M&A・提携分析
    Summary Exact Sciences Corp (Exact) is a molecular diagnostic company that focuses on the early detection and prevention of various cancers. The company’s flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of …
  • BG Medicine Inc:医療機器:M&Aディール及び事業提携情報
    Summary BG Medicine Inc (BGM), formerly Beyond Genomics Inc is a medical device company that discovers, develops and delivers diagnostic products. The company offers diagnostis products to aid in the clinical management of heart failure and related disorders. It offers BGM Galectin-3 test, an in vit …
  • Fuji Oil Holdings Inc.:戦略・SWOT・企業財務分析
    Fuji Oil Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Fuji Oil Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • AvivaSA Emeklilik ve Hayat A.S.:企業の戦略・SWOT・財務分析
    AvivaSA Emeklilik ve Hayat A.S. - Strategy, SWOT and Corporate Finance Report Summary AvivaSA Emeklilik ve Hayat A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • UTS Biogastechnik GmbH:企業の戦略的SWOT分析
    UTS Biogastechnik GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Stentys SA (STNT):企業の財務・戦略的SWOT分析
    Summary Stentys SA (Stentys) is a medical device company that designs, develops and markets self-expanding stents for the treatment of patients with acute myocardial infarction and coronary disease. The company’s products include xposition S self-applying stent, mistent biodegradable sirolimus relea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆